WO2022169339A1 - 신규 핵산 분자 - Google Patents
신규 핵산 분자 Download PDFInfo
- Publication number
- WO2022169339A1 WO2022169339A1 PCT/KR2022/001874 KR2022001874W WO2022169339A1 WO 2022169339 A1 WO2022169339 A1 WO 2022169339A1 KR 2022001874 W KR2022001874 W KR 2022001874W WO 2022169339 A1 WO2022169339 A1 WO 2022169339A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- cancer
- acid molecule
- protein
- antigen
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 213
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 202
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 202
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 148
- 102000036639 antigens Human genes 0.000 claims abstract description 99
- 108091007433 antigens Proteins 0.000 claims abstract description 99
- 239000000427 antigen Substances 0.000 claims abstract description 87
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 59
- 229960005486 vaccine Drugs 0.000 claims abstract description 53
- 201000011510 cancer Diseases 0.000 claims abstract description 44
- 230000009385 viral infection Effects 0.000 claims abstract description 41
- 208000036142 Viral infection Diseases 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 230000002265 prevention Effects 0.000 claims abstract description 18
- 101710198474 Spike protein Proteins 0.000 claims description 89
- 229940096437 Protein S Drugs 0.000 claims description 78
- 108010074328 Interferon-gamma Proteins 0.000 claims description 40
- 102100037850 Interferon gamma Human genes 0.000 claims description 36
- 102000009027 Albumins Human genes 0.000 claims description 25
- 108010088751 Albumins Proteins 0.000 claims description 25
- 102100038565 Mucin-like protein 1 Human genes 0.000 claims description 25
- 101710133580 Mucin-like protein 1 Proteins 0.000 claims description 25
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 21
- 108010076282 Factor IX Proteins 0.000 claims description 21
- 229960004222 factor ix Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 108010052285 Membrane Proteins Proteins 0.000 claims description 18
- 102000018697 Membrane Proteins Human genes 0.000 claims description 18
- 201000009030 Carcinoma Diseases 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 208000025721 COVID-19 Diseases 0.000 claims description 7
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 7
- 241000315672 SARS coronavirus Species 0.000 claims description 6
- 230000002489 hematologic effect Effects 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 229960000814 tetanus toxoid Drugs 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 201000005702 Pertussis Diseases 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 239000000693 micelle Substances 0.000 claims description 4
- 239000007908 nanoemulsion Substances 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 239000002479 lipoplex Substances 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000007659 Fibroadenoma Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000008771 Lymphadenopathy Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000013228 adenopathy Diseases 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 201000003149 breast fibroadenoma Diseases 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000002960 lipid emulsion Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920000575 polymersome Polymers 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 85
- 102000004169 proteins and genes Human genes 0.000 abstract description 77
- 230000003472 neutralizing effect Effects 0.000 abstract description 19
- 230000001965 increasing effect Effects 0.000 abstract description 16
- 241000700605 Viruses Species 0.000 abstract description 14
- 238000001727 in vivo Methods 0.000 abstract description 11
- 230000001939 inductive effect Effects 0.000 abstract description 8
- 230000028327 secretion Effects 0.000 abstract description 8
- 230000004727 humoral immunity Effects 0.000 abstract description 5
- 210000002865 immune cell Anatomy 0.000 abstract description 5
- 230000007969 cellular immunity Effects 0.000 abstract description 4
- 230000003834 intracellular effect Effects 0.000 abstract description 3
- 230000002147 killing effect Effects 0.000 abstract description 3
- 108050001049 Extracellular proteins Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 132
- 241001678559 COVID-19 virus Species 0.000 description 80
- 108020004705 Codon Proteins 0.000 description 67
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 30
- 108020004999 messenger RNA Proteins 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 230000028993 immune response Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 17
- 210000003071 memory t lymphocyte Anatomy 0.000 description 14
- 241000004176 Alphacoronavirus Species 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 241000282412 Homo Species 0.000 description 11
- 210000004988 splenocyte Anatomy 0.000 description 11
- 210000001280 germinal center Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000024932 T cell mediated immunity Effects 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 108700021021 mRNA Vaccine Proteins 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 6
- 102100032912 CD44 antigen Human genes 0.000 description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 6
- 101000941029 Homo sapiens Endoplasmic reticulum junction formation protein lunapark Proteins 0.000 description 6
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 6
- 101001043209 Homo sapiens Leukemia NUP98 fusion partner 1 Proteins 0.000 description 6
- 102100033467 L-selectin Human genes 0.000 description 6
- 102100021960 Leukemia NUP98 fusion partner 1 Human genes 0.000 description 6
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 6
- 102000004243 Tubulin Human genes 0.000 description 6
- 108090000704 Tubulin Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000028996 humoral immune response Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 229940126582 mRNA vaccine Drugs 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101710155891 Mucin-like protein Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000008904 Betacoronavirus Species 0.000 description 4
- 241000008920 Gammacoronavirus Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 229940022399 cancer vaccine Drugs 0.000 description 4
- 238000009566 cancer vaccine Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 description 3
- 101710102159 Atrial natriuretic peptide receptor 2 Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241001461743 Deltacoronavirus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 241000579048 Merkel cell polyomavirus Species 0.000 description 3
- 101000953880 Severe acute respiratory syndrome coronavirus 2 Membrane protein Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- -1 coatings Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 229940125575 vaccine candidate Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000711467 Human coronavirus 229E Species 0.000 description 2
- 241000482741 Human coronavirus NL63 Species 0.000 description 2
- 241001428935 Human coronavirus OC43 Species 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 2
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002809 long lived plasma cell Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 1
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020003564 Retroelements Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 108030001722 Tentoxilysin Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000015325 multicentric Castleman disease Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000029610 recognition of host Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to a nucleic acid molecule for preventing or treating a viral infection or cancer, comprising a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen.
- the present invention relates to a vaccine composition for preventing or treating a viral infection or cancer comprising the nucleic acid molecule.
- Vaccines are currently being developed and manufactured in various ways, and specific types are attenuated/live vaccines, which inject pathogens in an attenuated state, There are toxoid vaccines, subunit vaccines prepared by extracting only the antigenic determinants recognized as antigens, and recombinant vaccines prepared by separately producing only epitopes using genetic information. have.
- the recombinant vaccine has the advantage of high safety because it does not contain components other than the epitope.
- the nucleic acid vaccine made of mRNA has a high production rate and low cost, and has cell-mediated immunity and body fluids. There are many advantages in that it can induce an immune response against both humoral immunity.
- the composition of the vaccine can be designed in various ways, such as by selecting and using only a specific epitope that induces an immune response among various components of the antigen, which is useful for the prevention or treatment of various diseases such as viral infection and cancer. .
- viral infections range from relatively mild symptoms such as colds, influenza, chickenpox, and herpes labialis, rabies, Ebola, Marburg, Crimean Congo hemorrhagic fever virus disease, AIDS, avian influenza, SARS, COVID-19, cancer, etc.
- rabies rabies
- Ebola Marburg
- Crimean Congo hemorrhagic fever virus disease AIDS
- avian influenza SARS, COVID-19, cancer, etc.
- vaccines for preventing viral infections are being actively developed.
- cancer vaccines are being researched and developed for the purpose of preventing and treating cancers caused by mutations in cells as well as cancers caused by viral infection.
- Cancer cells have tumor-specific antigens that are not present in normal cells, and cancer vaccines kill cancer cells before they proliferate excessively by inducing a cancer cell-specific immune response through these tumor-specific antigens.
- Some cancer vaccines are also made customized for the patient. By analyzing the patient's cancer cell gene, the cancer-causing mutant gene is found, and mRNA converted into the neoantigen epitope encoded by it is prepared and administered as a vaccine. In this case, a strong immune response can be induced only in the patient, so it has the advantage that it can be developed as a customized precision medicine.
- nucleic acid vaccines such as mRNA vaccines
- protein expression efficiency is very important due to the nature of the mechanism of action, and the efficacy of the vaccine is determined according to the protein expression level.
- the development of materials is required.
- An object of the present invention is to provide a nucleic acid molecule for the prevention or treatment of viral infection or cancer comprising a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen, and a vaccine composition comprising the nucleic acid molecule.
- One aspect of the present invention provides a nucleic acid molecule for the prevention or treatment of viral infection or cancer, comprising a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen.
- signal peptide refers to a peptide present at the N-terminus of a protein at the beginning of protein synthesis, and a signal sequence, a targeting sequence, a localization signal, a localization sequence ( It is also called a localization sequence, a leader sequence, or a leader peptide.
- the signal peptide according to the present invention may serve to increase protein expression and secretion of nucleic acid molecules.
- the 'protein expression' or 'protein expression rate' may be used interchangeably with the same meaning as 'protein translation', 'protein translation rate', 'antigen expression', 'antigen expression rate', and the like.
- the signal peptide is a group consisting of IgE (Immunoglobulin E), albumin, interferon gamma (IFN- ⁇ ), factor IX and mucin-like protein 1 (MLP1). It may be derived from one or more selected from, but is not limited thereto.
- the signal peptide is SEQ ID NO: 1 derived from IgE, SEQ ID NO: 5 derived from albumin, SEQ ID NO: 9 derived from IFN- ⁇ , SEQ ID NO: 13 derived from factor IX, and SEQ ID NO: 17 derived from MLP1 It may be one or more selected from the group consisting of the indicated peptides, but is not limited thereto.
- nucleic acid encoding the signal peptide may be one or more selected from the group consisting of SEQ ID NOs: 2 to 4, 6 to 8, 10 to 12, 14 to 16, and 18 to 20, but is not limited thereto.
- antigen refers to a protein that induces an immune response such as specific antibody production and cytokine secretion
- the antigen is a coronavirus, oncovirus, tumor-specific antigen, It may be derived from one or more selected from the group consisting of a tumor-associated antigen and a neoantigen epitope.
- coronavirus alpha coronavirus genus ( ⁇ -CoV, alphaCoV, alphacoronavirus), beta coronavirus genus ( ⁇ -CoV, betaCoV, betacoronavirus), gamma coronavirus genus ( ⁇ -CoV, gammaCoV, gammacoronavirus) or delta It may belong to the corona virus genus ( ⁇ -CoV, deltaCoV, deltacoronavirus), and more specifically, HCoV-229E, HCoV-NL63, Bat-SARS-like (SL)-ZC45, Bat-SL ZXC21, SARS-CoV, MERS -CoV, HCoV-OC43, HKU-1, MHV-A59, or may be SARS-CoV-2, but is not limited thereto.
- the antigen may be one or more selected from the group consisting of a spike protein and a membrane protein derived from coronavirus.
- the antigen may be one or more selected from the group consisting of a spike protein and a membrane protein derived from coronavirus.
- the spike protein of the coronavirus according to the present invention can serve to induce an immune response and increase the ability to produce neutralizing antibodies, and the membrane protein induces an immune response, such as improving the function of CD4+ Th cells, thereby inducing a virus-infected It can play a role in killing cells.
- the oncovirus refers to a virus that causes tumors (cancer), and specifically, HBV (Hepatitis B virus), HCV (Hepatitis C virus), HTLV (Human T-lymphotropic virus), HPV (Human papillomaviruses), HHV -8 (Kaposi's sarcoma-associated herpesvirus), MCV (Merkel cell polyomavirus), or EBV (Epstein-Barr virus), but is not limited thereto.
- HBV Hepatitis B virus
- HCV Hepatitis C virus
- HTLV Human T-lymphotropic virus
- HPV Human papillomaviruses
- HHV -8 Kaposi's sarcoma-associated herpesvirus
- MCV Middle cell polyomavirus
- EBV Epstein-Barr virus
- the 'tumor-specific antigen', 'tumor-associated antigen', and 'new antigen epitope' refer to antigens or epitopes that are not present in normal cells and are specifically present only in cancer cells.
- a mutant gene caused by cancer cell-specific mutations such as mutational frameshift, splice variant, gene fusion, and endogenous retroelement, or from the mutant gene It may be expressed mRNA or protein.
- the antigen may be one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 21 and 26;
- the nucleic acid encoding the antigen may be one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 22 to 25, and 27 to 30, but is not limited thereto.
- a nucleic acid molecule according to the invention may comprise a nucleic acid encoding a Th cell epitope.
- Th cell epitope refers to a peptide that is recognized by Th cells and induces an immune response by Th cells
- the 'Th cells (T helper cell)' are CD4+ cells, CD4+ T cells, helper T lymphocytes, It refers to immune cells, also called helper T cells, etc.
- the Th cell epitope according to the present invention may serve to increase the ability to produce neutralizing antibodies by inducing an immune response by Th cells, specifically IFN- ⁇ , TNF- ⁇ , IL-2, IL-10, IL- 4, secretes various cytokines such as IL-5, IL-6, IL-9, IL-10, and IL-13 , and promotes the antibacterial activity of phagocytes including macrophages.
- the Th cell epitope may be a peptide derived from one or more selected from the group consisting of tetanus toxoid, diphtheria toxoid, and pertussis toxoid.
- the toxoid refers to a substance in which toxicity is removed but immunogenicity inducing an immune response remains, and 'tetanus toxoid' is tetanose, a neurotoxin produced by the tetanus bacteria Clostridium tetani .
- Th cell epitope is an epitope composed of a peptide sequence that is presented by MHC Class II of antigen-presenting cells such as macrophages or dendritic cells and sensed by T cell receptor of Th cells and transmits a stimulation signal.
- the Th cell epitope may further include a nucleic acid encoding a cleavage site, and may further include a nucleic acid sequence encoding a cleavage site between the antigen and the Th cell epitope.
- the term 'cleavage site' refers to a peptide that is cleaved by a proteolytic enzyme.
- the protein expressed from the nucleic acid molecule serves to allow the site recognized by the enzyme to be cleaved, and through this, each signal peptide, antigen and/or Th cell epitope linked to the nucleic acid molecule is enable it to perform its role.
- the cleavage site may be cleaved by an endogenous enzyme present in a cell, and specifically may be cleaved by a furine protease or a foot-and-mouth disease virus (FMDV) 2A self-cleavage site, but is not limited thereto.
- FMDV foot-and-mouth disease virus
- Th cell epitope may be the amino acid sequence of SEQ ID NO: 44;
- the nucleic acid encoding the Th cell epitope may be one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 45 and 46, but is not limited thereto.
- viral infection refers to a disease resulting from the proliferation of a virus in an organ or tissue of a human body.
- the viral infection may be a coronavirus infection.
- coronavirus infection Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus disease-2019 (COVID-19) consisting of It may be one or more selected from the group, but as long as it is a disease caused by a coronavirus infection, it is not limited thereto.
- the viral infection may be cancer.
- the cancer may be at least one selected from the group consisting of solid carcinoma and hematological carcinoma, and the solid carcinoma includes hepatocarcinoma, cervical cancer, anal cancer, and penis cancer. ), vulva cancer, vaginal cancer, oropharyngeal cancer, Kaposi's sarcoma, nasopharyngeal carcinoma, stomach cancer, multicentric Castleman's disease , primary effusion lymphoma or Merkel cell carcinoma, etc., and the hematological carcinoma includes T-cell leukemia, primary effusion lymphoma, Burkitt's lymphoma, etc. lymphoma), Hodgkin's lymphoma, or post-transplant lymphoproliferative disease, but as long as it is caused by oncovirus infection, it is not limited thereto.
- cancers that can be prevented by the nucleic acid molecule according to the present invention may be one or more selected from the group consisting of solid carcinomas and hematological carcinomas, and the solid carcinomas include gastric cancer, lung cancer, liver cancer, colorectal cancer, colon cancer, and kidney cancer.
- small intestine cancer pancreatic cancer, brain tumor, bone cancer, skin cancer, epidermal carcinoma, squamous cell carcinoma, breast cancer, sclerosing adenopathy, head and neck cancer, esophageal cancer, pharyngeal cancer, thyroid cancer, parathyroid cancer, neuroblastoma, melanoma, sarcoma, prostate cancer, uterine cancer, It may be cervical cancer, ovarian cancer, vaginal cancer, vulvar cancer, urethral cancer, bladder cancer, penile cancer, testicular cancer, fibroadenoma, or metastases thereof, and the hematological carcinoma includes hematological cancer, angiosarcoma, leukemia, lymphoma, or their It may be metastatic cancer, but is not limited thereto.
- nucleic acid molecule according to the present invention may be a nucleic acid molecule for the preparation of a vaccine, or a nucleic acid molecule for the preparation of a vaccine for the prevention or treatment of viral infection or cancer.
- prevention refers to any action in which a viral infection or cancer is inhibited or delayed by the nucleic acid molecule according to the present invention.
- treatment refers to any action in which symptoms of viral infection or cancer are improved or cured by the nucleic acid molecule according to the present invention.
- nucleic acid molecule has a meaning comprehensively encompassing DNA and RNA molecules, and the nucleotide, which is the basic structural unit in the nucleic acid molecule, includes not only natural nucleotides, but also analogs in which sugar or base sites are modified. .
- sequence of the nucleic acid molecule of the present invention may be mutated, said mutation comprising addition, deletion, non-conservative substitution or modification of one or more nucleotides.
- sequences used in the present invention are construed to include sequences exhibiting substantial identity to the sequences described in the sequence listing, given that mutations with biologically equivalent activity are considered.
- the term, 'substantial identity' refers to aligning the sequence of the present invention and any other sequences as much as possible, and analyzing the aligned sequence using an algorithm commonly used in the art. 60% homology, more specifically 70% homology, even more specifically 80% homology, most specifically 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% homology. , means a sequence showing 98% or 99% homology.
- sequence having high homology with the sequence represented by SEQ ID NOs: 1 to 59 of the present invention for example, having a high homology of 70% or more, specifically 80% or more, more specifically 90% or more Sequences should also be construed to be included within the scope of the present invention.
- the nucleic acid molecule may contain the signal peptide, antigen and/or Th cell epitope according to the present invention in the following structure: 5'-[signal peptide]-[antigen]-3' or 5'-[signal peptide ]-[antigen]-[Th cell epitope]-3'.
- the signal peptide, antigen and/or Th cell epitope is not limited to the above-described order, and the order is not limited as long as it can perform the role according to the present invention.
- the signal peptide, antigen and/or Th cell epitope may be included in the nucleic acid molecule singly or in plurality, and the number is not limited as long as the expression rate of the protein is not reduced.
- nucleic acid molecule is a general nucleic acid sequence for expression as a protein, in addition to the signal peptide, antigen and/or Th cell epitope, specifically, 5'-CAP including 7-methylguanosine, a Kozak sequence, a start codon, a stop codon, a 3'-Poly A tail including adenosine, and the like.
- Another aspect of the present invention provides a vaccine composition for preventing or treating viral infection or cancer, comprising the nucleic acid molecule.
- prevention refers to any action in which viral infection or cancer is suppressed or delayed by administration of the vaccine composition according to the present invention.
- treatment refers to any action in which symptoms of viral infection or cancer are improved or cured by administration of the vaccine composition according to the present invention.
- the term “vaccine” refers to an immunogen or antigenic substance that generates immunity in a living body of a subject by injecting or orally administering to the subject for the prevention of infection as a biological preparation containing an antigen that gives immunity to the subject.
- the vaccine may be an RNA vaccine, specifically, an mRNA vaccine.
- mRNA vaccine refers to a vaccine that induces an immune response by artificially replicating some of the genes of an antigen and then administering it. These mRNA vaccines have various advantages compared to the existing protein vaccines. First of all, there is no need to directly handle dangerous pathogens because they can be synthesized only with the genetic information of the pure target antigen. Even if it does, there is no concern that it will show any particular toxicity, and it has various advantages such as being able to rapidly develop vaccines against suddenly occurring infectious diseases or various mutations due to the simplicity of its composition only with mRNA.
- the vaccine composition for preventing or treating a viral infection or cancer according to the present invention may be used for the prevention or treatment of a coronavirus infection and/or cancer, and may include a coronavirus, a tumor virus, a tumor-specific antigen, a tumor- It may have immunity to the associated antigen and/or the new antigen epitope.
- coronavirus examples include alpha-coronavirus , beta-coronavirus, gamma-coronavirus or delta-coronavirus, more specifically HCoV-229E, HCoV-NL63, Bat-SARS-like (SL)-ZC45, Bat- It may be SL ZXC21, SARS-CoV, MERS-CoV, HCoV-OC43, HKU-1, MHV-A59 or SARS-CoV-2, and specific examples of the oncovirus include HBV, HCV, HTLV, HPV, HHV-8, It may be MCV or EBV, but is not limited thereto.
- the nucleic acid molecule included in the vaccine composition may be supported or linked to a carrier, and the carrier may be at least one selected from the group consisting of a liposome-based carrier, a lipid-based carrier, a polymer-based carrier, and a lipid-polymer hybrid nanoparticle.
- the present invention is not limited thereto.
- the carrier include liposomes, phytosomes, ethosomes, lipid nanoparticles, lipid-like nanoparticles, lipid emulsions, a liposome-based delivery system or a lipid-based delivery system such as lipoplex and lipid micelles; polymer-based carriers such as polymersomes, polymeric nanoparticles, dendrimers, nanospheres, polyplexes, and polymeric micelles; Or lipid-polymer hybrid nanoparticles, cationic nanoemulsion, anionic nanoemulsion, lipopolyplex, such as lipid-polymer hybrid nanoparticles, but may be , but is not limited thereto.
- the vaccine composition of the present invention may include a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, adjuvants, stabilizers, excipients, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like.
- the carrier include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, glycerin, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
- the vaccine composition of the present invention may be formulated in the form of oral dosage forms and sterile injection solutions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods.
- sterile injection solutions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods.
- it can be prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- the vaccine composition may be administered to a subject in various forms.
- the "administration" may be performed by subcutaneous administration, intramuscular administration, intradermal administration, intraperitoneal administration, intravenous administration, nasal administration, transdermal administration, parenteral administration and oral administration, but is not limited thereto.
- the vaccine composition may include one or more adjuvants and the like to improve or enhance an immune response.
- Suitable adjuvants include synthetic analogs of double-stranded RNA (dsRNA), oligonucleic acids of the unmethylated cytidine-guanidine type, peptides, aluminum hydroxide, aluminum phosphate, aluminum oxide and mineral or vegetable oils such as Marcol 52, and compositions comprising one or more emulsifiers or surface active substances such as risorcecithin, polyvalent cations, polyanions, and the like.
- Another aspect of the present invention provides a method for generating an immune response against a viral infection or cancer in an individual, comprising administering the vaccine composition to an individual in need thereof.
- the term, "individual” includes both an individual likely to be infected with a virus or an infected individual, or an individual likely to or has developed cancer, and may include, without limitation, humans, any non-human animals, fish or plants, and the like.
- the non-human animal may be a vertebrate, such as a primate, dog, cow, horse, pig, rodent, such as mouse, rat, hamster, guinea pig, and the like.
- the term “subject” may be used interchangeably with “subject” or “patient”.
- immune response means that an individual's immune system is activated in response to the introduction of an antigen.
- the immune response may be in the form of cell-mediated immunity, humoral immunity, or both.
- the vaccine composition of the present invention may contain an effective amount of an active ingredient, that is, a nucleic acid molecule according to the present invention together with a pharmaceutically acceptable carrier and adjuvant.
- an effective amount means an amount sufficient to induce a specific immune response against a viral infection or cancer in an individual to which the vaccine composition is administered.
- the effective amount can be readily determined by one of ordinary skill in the art, for example, can be determined through routine experimentation in animals.
- Another aspect of the present invention provides a method for preventing or treating a viral infection or cancer in an individual, comprising administering the vaccine composition to an individual in need thereof.
- the nucleic acid molecule according to the present invention has excellent intracellular protein expression rate and excellent ability to secrete protein to the outside of the cell.
- it when administered in vivo, it allows the individual to acquire humoral immunity, such as induction of antigen-specific neutralizing antibody, and to acquire cellular immunity, such as increasing the amount of immune cells directly involved in virus killing, It can be usefully utilized as a vaccine for the prevention and treatment of viral infections or cancer.
- ssRNA ladder is a size marker for measuring the size of mRNA
- No SP is a result of a nucleic acid molecule containing only a spike protein without a signal peptide
- Albumin SP is an albumin-derived signal peptide and a spike protein Results relating to nucleic acid molecules containing this result
- IFN- ⁇ SP refers to results relating to nucleic acid molecules containing IFN- ⁇ -derived signal peptide and spike protein
- Factor IX SP refers to Factor IX-derived signal peptide and spike protein.
- Mucin like protein SP is a result relating to a nucleic acid molecule containing an MLP1-derived signal
- ssRNA ladder is a size marker for measuring the size of mRNA
- No SP is a nucleic acid molecule that does not contain a signal peptide but contains only a membrane protein
- Albumin is an albumin-derived signal peptide and a membrane protein
- IFN- ⁇ refers to a nucleic acid molecule containing IFN- ⁇ -derived signal peptide and membrane protein
- Factor IX refers to a nucleic acid molecule containing a factor IX-derived signal peptide and membrane protein.
- MLP is a result relating to a nucleic acid molecule containing an MLP1-derived signal peptide and a membrane protein.
- Wild SP is a result of optimizing each signal peptide with a wild-type codon
- Yeast opti. SP is a result of optimizing each signal peptide with a yeast codon.
- FIG. 3 is an image showing the electrophoresis results of mRNA nucleic acid molecules in which SARS-CoV-2 virus spike protein (hereinafter referred to as 'spike protein') and Th cell epitope are fused as each signal peptide and antigen protein.
- SARS-CoV-2 virus spike protein hereinafter referred to as 'spike protein'
- Th cell epitope are fused as each signal peptide and antigen protein.
- ssRNA ladder is a size marker for measuring the size of mRNA
- No SP is a result of a nucleic acid molecule containing only a spike protein without a signal peptide
- Albumin SP is an albumin-derived signal peptide and a spike protein Results relating to nucleic acid molecules containing this result
- IFN- ⁇ SP refers to results relating to nucleic acid molecules containing IFN- ⁇ -derived signal peptide and spike protein
- Factor IX SP refers to Factor IX-derived signal peptide and spike protein.
- Mucin like protein SP is a result relating to a nucleic acid molecule containing an MLP1-derived signal peptide and a spike protein.
- Figure 4 is an image showing the amount of SARS-CoV-2 virus spike protein (hereinafter referred to as 'spike protein') expressed in cells, the amount of protein contained in the cell lysate transfected with each nucleic acid molecule it's about "Negative control” refers to the result of cells not transfected with the nucleic acid molecule (negative control), "No SP” refers to the result regarding the nucleic acid molecule containing only the spike protein without the signal peptide, and “IgE” refers to the IgE-derived signal Results regarding nucleic acid molecules containing peptides and spike proteins, “Albumin SP” results about nucleic acid molecules containing albumin-derived signal peptides and spike proteins, “IFN- ⁇ SP” results regarding IFN- ⁇ -derived signal peptides and spike proteins As a result of nucleic acid molecules containing this, “Factor IX SP” results on a nucleic acid molecule containing a signal peptide and spike protein derived from
- 5a is It is an image showing the amount of SARS-CoV-2 virus spike protein (hereinafter referred to as 'spike protein') expressed in cells.
- media relates to the amount of protein contained in the cell culture medium transfected with each nucleic acid molecule
- lysate relates to the amount of protein contained in the cell lysate transfected with each nucleic acid molecule.
- “Negative control” refers to the result of cells not transfected with the nucleic acid molecule (negative control)
- “No SP” refers to the result regarding the nucleic acid molecule containing only the spike protein without the signal peptide
- “Albumin SP” refers to the result of albumin-derived Results regarding nucleic acid molecules containing signal peptides and spike proteins
- “IFN- ⁇ SP” results regarding nucleic acid molecules containing IFN- ⁇ -derived signal peptides and spike proteins
- “Factor IX SP” indicates signal peptides derived from Factor IX and a result regarding a nucleic acid molecule containing a spike protein
- “Mucin like protein SP” is a result regarding a nucleic acid molecule containing an MLP1-derived signal peptide and a spike protein.
- 5B is an image showing the amount of ⁇ / ⁇ -tubulin protein expressed in the cells according to FIG. 5A and used as a loading control.
- 5c is It is an image showing the amount of SARS-CoV-2 virus spike protein (hereinafter referred to as 'spike protein') expressed in cells.
- media relates to the amount of protein contained in the cell culture medium transfected with each nucleic acid molecule
- lysate relates to the amount of protein contained in the cell lysate transfected with each nucleic acid molecule.
- “Negative control” refers to the results for cells not transfected with the nucleic acid molecule (negative control)
- “No SP” refers to the results for the nucleic acid molecule containing only the spike protein and Th cell epitope without the signal peptide
- "Albumin SP” “Results related to nucleic acid molecules containing albumin-derived signal peptides, spike proteins and Th cell epitopes
- “IFN- ⁇ SP” results related to nucleic acid molecules containing IFN- ⁇ -derived signal peptides, spike proteins and Th cell epitopes
- “Factor IX SP” refers to a nucleic acid molecule containing a signal peptide, spike protein and Th cell epitope derived from Factor IX
- “Mucin like protein SP” refers to a signal peptide derived from MLP1, a spike protein and a nucleic acid containing a Th cell epitope It is a molecular result.
- FIG. 5d is an image showing the amount of ⁇ / ⁇ -tubulin protein expressed in the cells according to FIG. 5c and used as a loading control.
- Figure 6a An image showing the amount of SARS-CoV-2 viral spike protein expressed in cells, including IgE-derived signal peptide and SARS-CoV-2 viral spike protein. Results for cells transfected with nucleic acid molecules (“STP2104”). “S0” refers to the SARS-CoV-2 viral spike protein total, and “S1” refers to subunit 1 of the SARS-CoV-2 viral spike protein. “ ⁇ / ⁇ -tubulin” was used as a loading control.
- 6b is As a graph showing the amount of SARS-CoV-2 virus spike protein detected in the cell culture medium, it contains IgE-derived signal peptide and SARS-CoV-2 viral spike protein. Results for cells transfected with nucleic acid molecules.
- the nucleic acid molecule was used at a concentration of 0.1 or 0.05 g/L.
- Ag1+LNP1 is an IgE-derived signal peptide and SARS-CoV-2 virus spike total protein.
- Ag2+LNP1 is an MLP1-derived signal peptide and SARS-CoV-2 virus spike total protein.
- Ag3+LNP1 is an IgE-derived signal peptide, SARS-CoV-2 virus spike total protein and Th cell epitope.
- results are related to nucleic acid molecules.
- RBD specific total IgG is a result regarding the amount of antibody specific to the RBD (receptor binding domain) domain among SARS-CoV-2 virus spike proteins
- S1 specific total IgG is a SARS-CoV-2 virus spike protein. Results regarding the amount of antibody specific for subunit 1 (S1) in the protein.
- FIG. 8 is a graph showing the amount of SARS-CoV-2 virus spike protein-specific neutralizing antibody formed in mice, and converted into a log value of a Plaque reduction neutralization test (PRNT) 50 value.
- Ag1+LNP1 is an IgE-derived signal peptide and SARS-CoV-2 virus spike total protein.
- Ag2+LNP1 is an MLP1-derived signal peptide and SARS-CoV-2 virus spike total protein.
- Ag3+LNP1 is an IgE-derived signal peptide, SARS-CoV-2 virus spike total protein and Th cell epitope.
- Results for nucleic acid molecules, "Mock” are results for Phosphate Buffered saline (PBS).
- FIG. 9a is a graph showing the amount of SARS-CoV-2 virus spike protein-specific binding antibodies (IgG1 and IgG2a isotype) formed in mice, including IgE-derived signal peptide and SARS-CoV-2 viral spike protein. Results for mice administered 1, 5 or 10 ⁇ g of the nucleic acid molecule. As a result of measurement at 4 weeks after the first (prime) inoculation, the amount of each antibody was expressed as optical density (OD).
- OD optical density
- “RBD protein” means that the amount of IgG1 and IgG2a antibodies specific for the receptor binding domain (RBD) domain among SARS-CoV-2 virus spike proteins increases with the amount of immunization.
- S protein is SARS-CoV- 2
- Figure 9b is a graph showing the amount of SARS-CoV-2 virus spike protein-specific binding antibody (IgG1 and IgG2a isotype) formed in mice, including IgE-derived signal peptide and SARS-CoV-2 virus spike protein Results for mice administered 1, 5 or 10 ⁇ g of the nucleic acid molecule.
- the amount of each antibody was expressed as optical density (OD).
- OD optical density
- RBD protein means that the amount of IgG1 and IgG2a antibodies specific for the receptor binding domain (RBD) domain among SARS-CoV-2 virus spike proteins increases with the amount of immunization.
- S protein is SARS-CoV- 2
- GC 10 is a graph showing the amount of germinal center (GC) B cells formed in mice, including IgE-derived signal peptide and SARS-CoV-2 virus spike total protein. Results for mice administered 1, 5 or 10 ⁇ g of the nucleic acid molecule.
- the humoral immune response involves the interaction between a special population of B cells and CD4+ T cells (follicular helper T cells (T FH cells)) in the germinal center (GC) to generate memory B cells and long-lived plasma cells.
- T FH cells follicular helper T cells
- FIG. 11 is a graph showing the amount of CD4 + central memory T cells (CD44 high+ and CD62L + cells among CD4 + cells) formed in mice.
- Including IgE-derived signal peptide and SARS-CoV-2 virus spike whole protein Splenocytes were isolated from mice administered with 1, 5, or 10 ⁇ g of nucleic acid molecules, and 15 mer-long peptides were synthesized with 9 mer overlaps with respect to the entire amino acid sequence of the spike, and then a peptide pool was constructed into five groups (peptide 1). to 5) among them, the results of flow cytometry analysis in which splenocytes were stimulated with peptide pool 2 in vitro.
- FIG. 12 is a graph showing the amount of CD8 + central memory T cells (CD44 high+ and CD62L + cells among CD8 + cells) formed in mice.
- CD8 + central memory T cells CD44 high+ and CD62L + cells among CD8 + cells.
- IgE-derived signal peptide and SARS-CoV-2 virus spike whole protein are the results obtained by isolating splenocytes from mice administered with 1, 5 or 10 ⁇ g of nucleic acid molecules and stimulating them with the SARS-CoV-2 virus spike protein-derived peptide pool 2 as described above.
- FIG. 13 is a graph showing the amount of CD8 + effector memory T cells (CD44 high+ and CD62L ⁇ cells among CD8 + cells) formed in mice.
- IgE-derived signal peptide and SARS-CoV-2 virus spike whole protein are the results obtained by isolating splenocytes from mice administered with 1, 5 or 10 ⁇ g of nucleic acid molecules and stimulating them with the SARS-CoV-2 virus spike protein-derived peptide pool 2 as described above.
- FIG. 14 is a graph showing the results of analyzing the number of IFN- ⁇ secreting cells formed in mice by ELISpot. Including IgE-derived signal peptide and SARS-CoV-2 virus spike whole protein Results regarding the number of cells secreting IFN- ⁇ in splenocytes isolated from mouse spleens administered at 1, 5 or 10 ⁇ g of nucleic acid molecules. "NC” is a result obtained without stimulation with peptide as a negative control, and "PP2" is a result obtained by stimulation with peptide pool 2 derived from SARS-CoV-2 virus spike protein as described above.
- IFN- ⁇ staining activity of IFN- ⁇ secreting cells formed in mice.
- IgE-derived signal peptide and SARS-CoV-2 virus spike whole protein are the results obtained by isolating splenocytes from mice administered with 1, 5 or 10 ⁇ g of nucleic acid molecules and stimulating them with the SARS-CoV-2 virus spike protein-derived peptide pool 2 as described above.
- nucleic acid molecules having excellent cell immunogenicity and ability to induce neutralizing antibody production, in particular, significantly increased protein expression were prepared.
- the expression rate of the antigen protein is increased to increase the cellular immunogenicity that causes an immune response, and accordingly, the neutralizing antibody in the human body is produced in a large amount within a short time. Furthermore, the immune response by Th cells is efficiently induced and cytokine secretion is increased, thereby showing the maximized preventive and/or therapeutic efficacy against viral infection or cancer.
- the nucleic acid molecule included a signal peptide, a Th cell epitope, and the like, and a specific antigen for the purpose of inducing prophylactic and/or therapeutic efficacy.
- the nucleotide sequences and amino acid sequences of the peptides and proteins were obtained from GenBank, and nucleic acid molecules with enhanced antigen protein expression efficiency were prepared by performing optimization with human or yeast codons for the wild-type sequence obtained from GenBank. Codon optimization optimizes by changing the codon preferred by each individual so that the gene encoding the protein can be expressed well.
- the amount of protein expression was predicted by calculating the GC content of the nucleic acid molecule and the free energy of the secondary mRNA structure. As the recognition efficiency by the ribosome increases, the protein expression rate may be increased.
- the signal peptide, antigen, Th cell epitope, etc. were constructed as follows to design a nucleic acid molecule: 5'-[signal peptide]-[antigen]-3' or 5'-[signal peptide]-[antigen] -[Th cell epitope]-3'.
- a signal peptide (SP) was first prepared.
- human-derived IgE immunoglobulin E
- albumin interferon gamma
- factor IX factor IX, F IX
- MLP1 mucin-like protein 1
- SEQ ID NO: 3 the nucleic acid sequence of SEQ ID NO: 3 is a form of codon-optimized IgE-derived signal peptide for humans.
- SP type SP codon order SEQ ID NO: IgE wild type (amino acid) MDWTWILFLV AAATRVHS SEQ ID NO: 1 wild type (nucleic acid) ATGGACTGGACCTGGATCCTCTTCTTGGTGGCAGCAGCCACGCGAGTCCACTCC SEQ ID NO: 2 human ATGGACTGGACCTGGATCCTGTTCCTGGTGGCCGCCGCTACAAGAGTGCACAGC SEQ ID NO: 3 leaven ATGGACTGGACTTGGATCTTGTTCTTGGTTGCTGCTGCCACCAGAGTCCACTCT SEQ ID NO: 4 albumin wild type (amino acid) MKWVTFISLL FLFSSAYS SEQ ID NO: 5 wild type (nucleic acid) ATGAAGTGGGTAACCTTTATTTCCCTTCTTTCTCTTTAGCTCGGCTTATTCC SEQ ID NO: 6 human ATGAAGTGGGTGACCTTCATCAGCCTGCTGTTCCTGTTTTCTTCCGCCTACAGC SEQ ID NO: 7 leaven ATGAAGTGGGTT
- Example 1-2-1 Production of 'SARS-CoV-2' spike protein
- the antigen of 'SARS-CoV-2' a virus that causes COVID-19, was used as an example.
- the spike protein (S) which is known to play a central role in infection and pathogenicity, such as receptor recognition of host cells, cell membrane fusion, and neutralizing antibody induction, was used. Then, codon optimization was performed by the method according to Example 1-1, and the results are shown in Table 2 below.
- the nucleic acid sequence of SEQ ID NO: 23 is a form in which the spike protein antigen of SARS-CoV-2 is codon-optimized for humans
- the nucleic acid sequence of SEQ ID NO: 25 is the spike protein antigen of SARS-CoV-2 for humans. It is a form with both codon-optimized and codon-optimized for yeast.
- SARS-CoV-2 spike protein wild type (amino acid) SEQ ID NO: 21 wild type (nucleic acid)
- SEQ ID NO: 22 human SEQ ID NO: 23 leaven SEQ ID NO: 24 Codon 250nt in yeast and codon 3569nt in humans
- SEQ ID NO: 25 SEQ ID NO: 25
- nucleic acid of SEQ ID NO: 25 having both yeast codons and human codons was used as an antigen to be used in the production of nucleic acid molecules for subsequent vaccines.
- Example 1-2-2 Production of 'SARS-CoV-2' membrane protein
- the antigen of 'SARS-CoV-2' a virus that causes COVID-19, was used as an example.
- the nucleic acid sequence of SEQ ID NO: 28 is a form in which the membrane protein antigen of SARS-CoV-2 is codon-optimized for humans
- the nucleic acid sequence of SEQ ID NO: 30 is the membrane protein antigen of SARS-CoV-2 for humans. It is a form with both codon-optimized and codon-optimized for yeast.
- nucleic acid of SEQ ID NO: 30 having both yeast codons and human codons was used as an antigen to be used in the production of nucleic acid molecules for subsequent vaccines.
- Example 1-3-1 Using 'SARS-CoV-2' spike protein as antigen
- nucleic acid molecule with increased protein expression efficiency In order to prepare a nucleic acid molecule with increased protein expression efficiency, first, five signal peptides obtained in Example 1-1 and SARS-CoV-2 virus spikes obtained in Example 1-2-1 A nucleic acid molecule to which a protein was fused was prepared.
- the spike protein was used in a form having both yeast codons and human codons, which are summarized in Table 4 below.
- SP type SP codon SARS-CoV-2 spike protein SEQ ID NO: IgE leaven Codon 250nt in yeast and codon 3569nt in humans SEQ ID NO: 31 albumin leaven SEQ ID NO: 32 IFN- ⁇ leaven SEQ ID NO: 33 F IX leaven SEQ ID NO: 34 MLP1 leaven SEQ ID NO: 35
- the transcription reaction mixture was incubated at 37° C. for 2 hours. Whether or not mRNA was synthesized was confirmed by electrophoresis using a 1% agarose gel containing Lonza GelStarTM Nucleic Acid gel Stain (catalog #5 0535). Meanwhile, the synthesized mRNA was purified using an Oligo (dT) column (via separation, catalog # 311.1219-2) in AKTA (Cytiva, AKTA york), and used for subsequent in vitro or in vivo experiments.
- Example 1-3-2 Using 'SARS-CoV-2' membrane protein as antigen
- nucleic acid molecule with increased protein expression efficiency In order to prepare a nucleic acid molecule with increased protein expression efficiency, first, the four signal peptides obtained in Example 1-1 and the SARS-CoV-2 virus membrane obtained in Example 1-2-2 Nucleic acid molecules fused with proteins were prepared, which are summarized in Table 5 below.
- SP type SP codon SARS-CoV-2 membrane protein SEQ ID NO: albumin wild type Codon 250nt in yeast and codon 419nt in humans SEQ ID NO: 36 leaven SEQ ID NO: 37 IFN- ⁇ wild type SEQ ID NO: 38 leaven SEQ ID NO: 39 F IX wild type SEQ ID NO: 40 leaven SEQ ID NO: 41 MLP1 wild type SEQ ID NO: 42 leaven SEQ ID NO: 43
- Example 1-3-1 After synthesizing the nucleic acid molecule into mRNA, its synthesis was confirmed, and the synthesized mRNA was also purified.
- a Th cell epitope was first prepared.
- Th cell epitope As an example, a Th cell epitope derived from tetanus toxoid (Tetanus Toxoid Th cell epitope, TTTh) was used. In addition, the TTTh was connected to a cleavage site (CS) having different sequences. The Th cell epitope containing the cleavage site was constructed to be located at the C-terminus of the ORF by including a stop codon as follows: 5'-[CS1]-[TTTh1]-[CS2]-[TTTh2]- [Stop codon]-3'.
- the specific amino acid sequence corresponding to the above configuration is as follows: 5'-[RQKR]-[IDKISDVSTIVPYIGPALNI]-[PKKR]-[NNFTVSFWLRVPKVSASHLE]-5'. Then, codon optimization was performed by the method according to Example 1-1, which is summarized in Table 6 below.
- the nucleic acid sequence of SEQ ID NO: 46 is a codon-optimized form of TTTh for humans.
- Th cells epitope Th cells epitope codon order SEQ ID NO: wild type (amino acid) RQKRIDKISD VSTIVPYIGP ALNIPKKRNN FTVSFWLRVP KVSASHLE SEQ ID NO: 44 wild type (nucleic acid) CGCCAGAAACGCATTGATAAAATTAGCGATGATGAGCACCATTGTGCCGTATATTGGCCCGGCGCTGAACATTCCGAAAAAACGCAACAACTTTACCGTGAGCTTTTGGCTGCGCGTGCCGAAAGTGAGCGCGAGCCATCTGGAATGA SEQ ID NO: 45 human AGACAGAAAAGAATCGATAAGATCAGCGACGTGTCTACAATCGTGCCATACATCGGCCCTGCCCTGAATATCCCCAAGAAGCGGAACAACTTCACCGTCAGCTTCTGGCTGAGAGTGCCTAAGGTGTCCGCCAGCCACCTGGAGTGA SEQ ID NO: 46
- the form having a human codon has a high Th cell epitope expression rate in human cells, and also exhibits a desired vaccine effect to an excellent degree.
- Example 1-5-1 Using 'SARS-CoV-2' spike protein as antigen
- the signal peptide proven to have a high protein expression rate was a form having a yeast codon
- the antigen 'SARS-CoV-2' spike protein demonstrated to have a high protein expression rate was It was confirmed that the form has both yeast and human codons.
- a nucleic acid molecule was prepared by fusing a Th cell epitope sequence to the signal peptide sequence and antigen sequence identified as described above. The sequence is summarized in Table 7 below.
- SP type SP codon antigen Th cells epitope SEQ ID NO: IgE yeast codon SARS-CoV-2 spike protein (250nt codon in yeast and 3569nt codon in human) human codon SEQ ID NO: 47 albumin SEQ ID NO: 48 IFN- ⁇ SEQ ID NO: 49 F IX SEQ ID NO: 50 MLP1 SEQ ID NO: 51
- the nucleic acid molecule was synthesized into mRNA, and whether or not the mRNA was synthesized was checked, and the synthesized mRNA was also purified.
- Example 1-5-2 Using 'SARS-CoV-2' membrane protein as antigen
- the signal peptide demonstrated to have a high protein expression rate had a wild-type codon or a yeast codon, and the antigen 'SARS-CoV' demonstrated high protein expression rate It was confirmed that the -2' membrane protein has both yeast and human codons.
- a nucleic acid molecule was prepared by fusing a Th cell epitope sequence to the signal peptide sequence and antigen sequence identified as described above. The sequence is summarized in Table 8 below.
- SP type SP codon antigen Th cells epitope SEQ ID NO: albumin wild type SARS-CoV-2 membrane protein (codon 250 nt in yeast and codon 419 nt in human) human codon SEQ ID NO: 52 leaven SEQ ID NO: 53 IFN- ⁇ wild type SEQ ID NO: 54 leaven SEQ ID NO: 55 F IX wild type SEQ ID NO: 56 leaven SEQ ID NO: 57 MLP1 wild type SEQ ID NO: 58 leaven SEQ ID NO: 59
- Example 2-1 Analysis of protein expression level of nucleic acid molecules for vaccines
- the protein expression rate was analyzed in vitro. In general, when exhibiting high expression characteristics in vitro, it is known that high immunogenicity is exhibited in vivo, thereby increasing the efficacy of vaccines.
- the effect on the nucleic acid molecules prepared in Examples 1-3-1 or 1-5-1 was confirmed.
- SARS-CoV-2 virus spike total protein (SEQ ID NO: 21) having both yeast codon and human codon was used, and as the signal peptide, all optimized with yeast codon, derived from IgE (SEQ ID NO: 4) , albumin-derived (SEQ ID NO: 8), interferon gamma-derived (SEQ ID NO: 12), factor IX-derived (SEQ ID NO: 16) or MLP1-derived (SEQ ID NO: 20) were used, and the Th cell epitope was optimized with human codons. (SEQ ID NO: 46).
- HEK-293T (ATCC, catalog number CRL-1586) cells were cultured in DMEM medium containing 10% FBS and 1% Pen/Strep, and 4 ⁇ 10 5 cells/well of HEK-293T cells were subjected to the above procedure.
- Nucleic acid molecules prepared according to the example were transfected at a concentration of about 0.1 or 0.05 g/L.
- the nucleic acid molecule was formulated into mRNA-LNP, which was supported on lipid nanoparticles (LNP) as a carrier, and used.
- LNP lipid nanoparticles
- a SARS-CoV-2 spike RBD polyclonal antibody (E-AB-V1006, Elabscience) was used as a primary antibody against the lysate of the transfected cells, and HRP-conjugated as a secondary antibody. This was performed using a secondary antibody (goat anti-rabbit IgG; ABclonal).
- ELISA was performed using the SARS-CoV-2 Spike S1 protein ELISA kit (RK04154, ABclonal) for the culture medium of the transfected cells.
- the spike protein of SARS-CoV-2 used as an antigen is composed of subunit 1 (S1) and subunit 2 (S2), and RBD (receptor binding domain), which is known to play a major role in cell infection, is located in S1.
- S1 subunit 1
- S2 subunit 2
- RBD receptor binding domain
- the nucleic acid molecule containing the SARS-CoV-2 virus spike protein according to the present invention and the signal peptide derived from IgE, albumin, IFN- ⁇ , factor IX or MLP1-derived in the cell. It was confirmed that the protein was well expressed.
- the nucleic acid molecule containing the SARS-CoV-2 virus spike protein according to the present invention and the signal peptide derived from albumin, IFN- ⁇ , factor IX or MLP1 is a protein in the cell. It was confirmed that the expression was well achieved, and the protein expressed in the cell was smoothly secreted out of the cell.
- the SARS-CoV-2 virus spike protein according to the present invention albumin, IFN- ⁇ , factor IX, or MLP1-derived signal peptide, and Th cell epitope are included. It was confirmed that the nucleic acid molecule was well expressed as a protein in the cell, and it was confirmed that the protein expressed in the cell was smoothly secreted out of the cell.
- the amount of protein contained in the culture medium was greater than the amount of protein contained in the cell lysate.
- the protein amount of the nucleic acid molecule containing the signal peptide was higher in the culture medium, and the signal peptide was added in the cell lysate. It was confirmed that the protein amount of the nucleic acid molecule not containing it was higher. Through this, it was confirmed that the extracellular secretion of the spike protein can be promoted by the signal peptide.
- nucleic acid molecule including the SARS-CoV-2 virus spike protein and IgE-derived signal peptide according to the present invention was well expressed in cells.
- the nucleic acid molecule containing the SARS-CoV-2 virus spike protein according to the present invention is well expressed in cells, so that a significant amount of the protein is secreted out of the cell by spike protein ELISA. confirmed through.
- spike protein ELISA spike protein ELISA
- the nucleic acid molecule according to the present invention which is composed of mRNA-LNP preparation and includes each signal peptide and SARS-CoV-2 virus spike protein as antigens, is expressed as a protein with high efficiency in cells, in particular, the expressed Since the protein can be secreted out of the cell, this shows that the secreted antigen protein can induce a cellular or humoral immune response by stimulating other immune cells existing in the body. Accordingly, the nucleic acid molecule according to the present invention can exhibit a desired vaccine function when administered in vivo.
- Example 2-2 Humoral immunity enhancing effect of nucleic acid molecules for vaccines
- nucleic acid molecule prepared in Example 1 In order to confirm the immunological efficacy of the nucleic acid molecule prepared in Example 1, it was confirmed whether the nucleic acid molecule exhibits an actual preventive effect on viral infection by inducing a humoral immune response to the antigen when administered in vivo. Among the nucleic acid molecules prepared in Example 1, the effect on the nucleic acid molecules prepared in Example 1-3-1 or Example 1-5-1 was confirmed.
- SARS-CoV-2 virus spike whole protein (SEQ ID NO: 21) having both yeast codon and human codon was used, and as the signal peptide, optimized with yeast codon, IgE-derived (SEQ ID NO: 4) or MLP1-derived (SEQ ID NO: 20) was used, and a Th cell epitope was prepared using a human codon-optimized one (SEQ ID NO: 46).
- the nucleic acid molecule It was formulated with mRNA-LNP, which was intramuscularly injected into the upper thigh at 4-week intervals in 6-week-old female BALB/c mice (6 mice) twice (1st: prime, 2nd: boost) and sacrificed at 3 weeks. did it At this time, the nucleic acid molecule was injected at a concentration of 1, 5 or 10 ⁇ g/individual. As a control group, PBS was injected.
- the level of a specific binding antibody or neutralizing antibody to the SARS-CoV-2 virus spike protein as an antigen in the serum of the immunized mouse was measured through ELISA or PRNT (Plaque Reduction Neutralizing Test) assay.
- ELISA ELISA Reduction Neutralizing Test
- PRNT Plaque Reduction Neutralizing Test
- an anti-mouse IgG1- (Invitrogen, Carlsbad, CA, USA) antibody or an anti-mouse IgG2a- (Novus, Centennial, CO, USA) antibody was used.
- splenocytes were isolated from the immunized mice, and the splenocytes were treated with a peptide derived from SARS-CoV-2 virus spike protein at a concentration of 2 mg/ml and cultured for 24 hours. After the culture was completed, immunostaining with each specific antibody was performed and flow cytometry was performed.
- FIGS. 7 to 9B it was confirmed that, after inoculation of the nucleic acid molecule, a high level of antibody binding to RBD or Spike total protein was produced in mice.
- the amount of the produced binding antibody and the neutralizing antibody increased in a concentration-dependent manner with respect to the nucleic acid molecule ( FIGS. 7 to 9b ), and the amount of the neutralizing antibody produced after the second inoculation compared to the first inoculation was about twice or more. It was confirmed that the increase (FIGS. 9a and 9b).
- the nucleic acid molecule composed of the mRNA-LNP preparation can efficiently induce a humoral immune response to the SARS-CoV-2 virus spike protein, thereby preventing and improving SARS-CoV-2 virus infection. Or it suggests that it may be usefully used for treatment.
- the nucleic acid molecule prepared in Example 1 In order to confirm the immunological efficacy of the nucleic acid molecule prepared in Example 1, it was confirmed whether the nucleic acid molecule exhibits a preventive effect against an actual viral infection by inducing a cellular immune response to the antigen when administered in vivo. As a type of cellular immune response, it was confirmed whether the production of T cells, such as effector memory T cells and central memory T cells, could be increased. Effector memory T cells provide an immediate but not lasting defense at the site of pathogen entry, and central memory T cells maintain the immune response by proliferating in secondary lymphoid organs to generate new effector cells.
- T cells such as effector memory T cells and central memory T cells
- a nucleic acid molecule according to the present invention comprising an mRNA-LNP preparation was injected into mice, and splenocytes were isolated from the immunized mice, followed by SARS-CoV -2 After treating the peptide (peptide pool 2) derived from the viral spike protein at a concentration of 2 mg/ml, flow cytometry was performed.
- CD4 + central memory T cells CD44 high+ and CD62L + cells in CD4 + cells
- CD8 + central memory T cells CD44 high+ and CD62L + cells in CD8 + cells
- CD8 + effector memory T cells CD8 + The proportion of CD44 high+ and CD62L ⁇ cells in the cells) was analyzed.
- the nucleic acid molecule composed of the mRNA-LNP preparation can efficiently induce a cellular immune response to the SARS-CoV-2 virus spike protein, thereby preventing and improving SARS-CoV-2 virus infection. Or it suggests that it may be usefully used for treatment.
- IFN- ⁇ secreting cells As a type of cellular immune response.
- IFN- ⁇ is an important component responsible for the innate antiviral response and is mainly produced by NK cells or innate lymphocyte type 1 cells. When IFN- ⁇ production by these immune cells is not made, virus replication in vivo increases.
- Example 1 the effect on the nucleic acid molecules prepared in Example 1-3-1 or Example 1-5-1 was confirmed.
- SARS-CoV-2 virus spike whole protein SEQ ID NO: 21
- yeast codon SEQ ID NO: 4
- MLP1-derived SEQ ID NO: 20
- splenocytes were isolated from mice immunized according to Example 2-2, and the splenocytes were treated with a SARS-CoV-2 virus spike protein-derived peptide (peptide pool 2) at a concentration of 2 mg/ml. Incubated for 48 hours. After completion of the culture, IFN- ⁇ secreting cells were detected using an ELISpot basic kit (Mabtech, Nacka Strand, Sweden).
- FIGS. 14 and 15 when the nucleic acid molecule was inoculated into a mouse, it was confirmed that the number of IFN- ⁇ secreting cells was significantly increased compared to that of a non-inoculated mouse ( FIG. 14 ). In addition, it was confirmed that the activity of IFN- ⁇ by the cells also significantly increased by about 3000 or more ( FIG. 15 ).
- the nucleic acid molecule composed of the mRNA-LNP preparation can efficiently induce a cellular immune response to the SARS-CoV-2 virus spike protein, thereby preventing and improving SARS-CoV-2 virus infection. Or it suggests that it may be usefully used for treatment.
- the plaque reduction neutralizing titer (PRNT) assay is a widely accepted approach for measuring virus neutralizing and protective antibodies to viruses and for assessing the immunogenicity of vaccines.
- SARS-CoV-2 virus (NCCP 43326, S-type) was added to the serum isolated from mice immunized according to Example 2-2 at a concentration of 4.5x10 2 PFU/ml and cultured for 1 hour. . Then, the serum-virus culture was added to Vero E6 cells (ATCC, catalog number CRL-1586) and incubated for 1 hour to infect the cells with the virus, and the PRNT was assayed according to a method known in the art. carried out.
- nucleic acid molecule composed of the mRNA-LNP preparation can efficiently generate neutralizing antibodies to the SARS-CoV-2 virus spike protein, thereby preventing, improving or treating SARS-CoV-2 virus infection. suggest that it can be useful for
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
SP 종류 |
SP 코돈 |
서열 | 서열번호 |
IgE | 야생형 (아미노산) |
MDWTWILFLV AAATRVHS | 서열번호 1 |
야생형 (핵산) |
ATGGACTGGACCTGGATCCTCTTCTTGGTGGCAGCAGCCACGCGAGTCCACTCC | 서열번호 2 | |
인간 | ATGGACTGGACCTGGATCCTGTTCCTGGTGGCCGCCGCTACAAGAGTGCACAGC | 서열번호 3 | |
효모 | ATGGACTGGACTTGGATCTTGTTCTTGGTTGCTGCTGCCACCAGAGTCCACTCT | 서열번호 4 | |
알부민 | 야생형 (아미노산) |
MKWVTFISLL FLFSSAYS | 서열번호 5 |
야생형 (핵산) |
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCC | 서열번호 6 | |
인간 | ATGAAGTGGGTGACCTTCATCAGCCTGCTGTTCCTGTTTTCTTCCGCCTACAGC | 서열번호 7 | |
효모 | ATGAAGTGGGTTACTTTCATCTCTTTGTTGTTTTTATTCTCCTCTGCTTACTCC | 서열번호 8 | |
IFN-γ | 야생형 (아미노산) |
MKYTSYILAF QLCIVLGSLG CYC | 서열번호 9 |
야생형 (핵산) |
ATGAAATATACAAGTTATATCTTGGCTTTTCAGCTCTGCATCGTTTTGGGTTCTCTTGGCTGTTACTGC | 서열번호 10 | |
인간 | ATGAAGTACACCAGCTACATCCTGGCCTTCCAGCTGTGCATCGTGCTGGGCTCTCTGGGCTGTTACTGC | 서열번호 11 | |
효모 | ATGAAGTACACTTCTTACATTTTGGCTTTCCAATTGTGTATCGTTTTGGGTTCCTTAGGTTGTTACTGT | 서열번호 12 | |
F IX | 야생형 (아미노산) |
MQRVNMIMAE SPGLITICLL GYLLSAEC | 서열번호 13 |
야생형 (핵산) |
ATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGT | 서열번호 14 | |
인간 | ATGCAGAGAGTGAACATGATCATGGCCGAGTCTCCTGGCCTGATCACCATCTGCCTGCTGGGCTACCTGCTGAGCGCCGAATGT | 서열번호 15 | |
효모 | ATGCAAAGAGTTAACATGATTATGGCTGAATCTCCAGGTTTGATCACTATCTGTTTGTTGGGTTACTTGTTATCCGCCGAATGT | 서열번호 16 | |
MLP1 | 야생형 (아미노산) |
MVYKTLFALC ILTAGWRVQS | 서열번호 17 |
야생형 (핵산) |
ATGGTCTACAAGACTCTCTTCGCTCTTTGCATCTTAACTGCAGGATGGAGGGTACAGAGT | 서열번호 18 | |
인간 | ATGGTGTACAAGACCCTGTTCGCCCTGTGCATCCTGACCGCCGGCTGGAGGGTGCAGAGC | 서열번호 19 | |
효모 | ATGGTATATAAAACTTTATTTGCTTTATGTATTTTAACTGCTGGTTGGCGTGTACAATCT | 서열번호 20 |
항원 종류 | 항원 코돈 | 서열번호 |
SARS-CoV-2 스파이크 단백질 |
야생형 (아미노산) | 서열번호 21 |
야생형 (핵산) | 서열번호 22 | |
인간 | 서열번호 23 | |
효모 | 서열번호 24 | |
효모의 코돈 250nt 및 인간의 코돈 3569nt | 서열번호 25 |
항원 종류 | 항원 코돈 | 서열번호 |
SARS-CoV-2 막 단백질 |
야생형 (아미노산) | 서열번호 26 |
야생형 (핵산) | 서열번호 27 | |
인간 | 서열번호 28 | |
효모 | 서열번호 29 | |
효모의 코돈 250nt 및 인간의 코돈 419nt | 서열번호 30 |
SP 종류 | SP 코돈 | SARS-CoV-2 스파이크 단백질 | 서열번호 |
IgE | 효모 | 효모의 코돈 250nt 및 인간의 코돈 3569nt | 서열번호 31 |
알부민 | 효모 | 서열번호 32 | |
IFN-γ | 효모 | 서열번호 33 | |
F IX | 효모 | 서열번호 34 | |
MLP1 | 효모 | 서열번호 35 |
SP 종류 | SP 코돈 | SARS-CoV-2 막 단백질 | 서열번호 |
알부민 | 야생형 | 효모의 코돈 250nt 및 인간의 코돈 419nt | 서열번호 36 |
효모 | 서열번호 37 | ||
IFN-γ | 야생형 | 서열번호 38 | |
효모 | 서열번호 39 | ||
F IX | 야생형 | 서열번호 40 | |
효모 | 서열번호 41 | ||
MLP1 | 야생형 | 서열번호 42 | |
효모 | 서열번호 43 |
Th 세포 에피토프 |
Th 세포 에피토프 코돈 |
서열 | 서열번호 |
야생형 (아미노산) |
RQKRIDKISD VSTIVPYIGP ALNIPKKRNN FTVSFWLRVP KVSASHLE | 서열번호 44 | |
야생형 (핵산) |
CGCCAGAAACGCATTGATAAAATTAGCGATGTGAGCACCATTGTGCCGTATATTGGCCCGGCGCTGAACATTCCGAAAAAACGCAACAACTTTACCGTGAGCTTTTGGCTGCGCGTGCCGAAAGTGAGCGCGAGCCATCTGGAATGA | 서열번호 45 | |
인간 | AGACAGAAAAGAATCGATAAGATCAGCGACGTGTCTACAATCGTGCCATACATCGGCCCTGCCCTGAATATCCCCAAGAAGCGGAACAACTTCACCGTCAGCTTCTGGCTGAGAGTGCCTAAGGTGTCCGCCAGCCACCTGGAGTGA | 서열번호 46 |
SP 종류 | SP 코돈 | 항원 | Th 세포 에피토프 |
서열번호 |
IgE | 효모 코돈 | SARS-CoV-2 스파이크 단백질 (효모의 코돈 250nt 및 인간의 코돈 3569nt) |
인간 코돈 | 서열번호 47 |
알부민 | 서열번호 48 | |||
IFN-γ | 서열번호 49 | |||
F IX | 서열번호 50 | |||
MLP1 | 서열번호 51 |
SP 종류 | SP 코돈 | 항원 | Th 세포 에피토프 |
서열번호 |
알부민 | 야생형 | SARS-CoV-2 막 단백질 (효모의 코돈 250nt 및 인간의 코돈 419nt) | 인간 코돈 | 서열번호 52 |
효모 | 서열번호 53 | |||
IFN-γ | 야생형 | 서열번호 54 | ||
효모 | 서열번호 55 | |||
F IX | 야생형 | 서열번호 56 | ||
효모 | 서열번호 57 | |||
MLP1 | 야생형 | 서열번호 58 | ||
효모 | 서열번호 59 |
Claims (16)
- IgE(Immunoglobulin E), 알부민(albumin), 인터페론 감마(IFN-γ), 인자 IX(factor IX) 및 뮤신-유사 단백질 1(mucin-like protein 1)으로 이루어진 그룹에서 선택된 하나 이상으로부터 유래된 시그널 펩타이드를 인코딩하는 핵산; 및 항원을 인코딩하는 핵산을 포함하는, 바이러스 감염증 또는 암의 예방 또는 치료용 핵산 분자.
- 제1항에 있어서,상기 시그널 펩타이드를 인코딩하는 핵산은 서열번호 2 내지 4, 6 내지 8, 10 내지 12, 14 내지 16, 및 18 내지 20으로 이루어진 그룹에서 선택된 하나 이상인, 핵산 분자.
- 제1항에 있어서,상기 항원은 코로나바이러스, 종양바이러스(oncovirus), 종양-특이적 항원(cancer tumor-specific antigen), 종양-연관 항원(tumor-associated antigen) 및 신항원 에피토프(neoantigen epitope)로 이루어진 그룹에서 선택된 하나 이상으로부터 유래된 것인, 핵산 분자.
- 제1항에 있어서,상기 항원은 코로나바이러스 유래의 스파이크 단백질 및 막 단백질로 이루어진 그룹에서 선택된 하나 이상인, 핵산 분자.
- 제1항에 있어서,상기 항원을 인코딩하는 핵산은 서열번호 22 내지 25, 및 27 내지 30으로 이루어진 그룹에서 선택된 하나 이상인, 핵산 분자.
- 제1항에 있어서,상기 핵산 분자는 Th 세포 에피토프를 인코딩하는 핵산을 포함하는, 핵산 분자.
- 제6항에 있어서,상기 Th 세포 에피토프는 파상풍 톡소이드(Tetanus toxoid), 디프테리아 톡소이드(DTH toxoid) 및 백일해 톡소이드(Purtussis toxoid)로 이루어진 그룹에서 선택된 하나 이상으로부터 유래된 것인, 핵산 분자.
- 제6항에 있어서,상기 Th 세포 에피토프를 인코딩하는 핵산은 서열번호 45 및 46으로 이루어진 그룹에서 선택된 하나 이상인, 핵산 분자.
- 제1항에 있어서,상기 바이러스 감염증은 코로나바이러스 감염증인, 핵산 분자.
- 제9항에 있어서,상기 코로나바이러스 감염증은 중증 급성 호흡기 증후군(Severe Acute Respiratory Syndrome, SARS), 중동 호흡기 증후군(Middle East Respiratory Syndrome, MERS) 및 코로나바이러스감염증-19(Coronavirus disease-2019, COVID-19)으로 이루어진 그룹에서 선택된 하나 이상인, 핵산 분자.
- 제1항에 있어서,상기 암은 고형암종 및 혈액암종으로 이루어진 그룹에서 선택된 하나 이상인, 핵산 분자.
- 제11항에 있어서,상기 암은 위암, 폐암, 간암, 대장암, 결장암, 신장암, 소장암, 췌장암, 뇌종양, 골암, 피부암, 표피암종, 편평세포암종, 유방암, 경화성선증, 두경부암, 식도암, 인두암, 갑상선암, 부갑상선암, 신경 모세포종, 흑색종, 육종, 전립선암, 자궁암, 자궁경부암, 난소암, 질암, 외음암, 요도암, 방광암, 음경암, 고환암, 혈액암, 혈관육종, 백혈병, 림프종, 섬유선종, 및 이들의 전이암으로 이루어진 군으로부터 선택되는 하나 이상인, 핵산 분자.
- 제1항의 핵산 분자를 포함하는, 바이러스 감염증 또는 암의 예방 또는 치료용 백신 조성물.
- 제13항에 있어서,상기 핵산 분자는 전달체에 담지 또는 연결된 것인, 백신 조성물.
- 제14항에 있어서,상기 전달체는 리포좀 기반 전달체, 지질 기반 전달체, 폴리머 기반 전달체 및 지질-폴리머 하이브리드 나노입자로 이루어진 그룹에서 선택된 하나 이상인, 백신 조성물.
- 제15항에 있어서,상기 전달체는 리포좀(liposome), 파이토좀(phytosome), 에토좀(ethosome), 지질 나노입자(lipid nanoparticle), 지질-유사 나노입자(lipid-like nanoparticle), 지질 에멀젼(lipid emulsion), 리포플렉스(lipoplex), 지질 미셸(lipid micelle), 폴리머좀(polymersome), 폴리머성 나노입자(polymeric nanoparticle), 덴드리머(dendrimer), 나노스피어(nanophere), 폴리플렉스(polyplex), 폴리머성 미셸(polymeric micelle), 지질-폴리머 하이브리드 나노입자(lipid-polymer hybrid nanoparticle), 양이온성 나노에멀젼(cationic nanoemulsion), 음이온성 나노에멀젼(anionic nanoemulsion) 및 리포폴리플렉스(lipopolyplex)로 이루어진 그룹에서 선택된 하나 이상인, 백신 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22750088.1A EP4306641A1 (en) | 2021-02-05 | 2022-02-07 | Novel nucleic acid molecule |
JP2023547642A JP2024507733A (ja) | 2021-02-05 | 2022-02-07 | 新規核酸分子 |
CN202280026988.1A CN117120617A (zh) | 2021-02-05 | 2022-02-07 | 新型核酸分子 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210017115 | 2021-02-05 | ||
KR10-2021-0017115 | 2021-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022169339A1 true WO2022169339A1 (ko) | 2022-08-11 |
Family
ID=82741441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/001874 WO2022169339A1 (ko) | 2021-02-05 | 2022-02-07 | 신규 핵산 분자 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4306641A1 (ko) |
JP (1) | JP2024507733A (ko) |
KR (1) | KR102553857B1 (ko) |
CN (1) | CN117120617A (ko) |
WO (1) | WO2022169339A1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190003471A (ko) * | 2016-02-25 | 2019-01-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 지카 바이러스에 대항하는 신규한 백신 |
WO2020092880A1 (en) * | 2018-11-02 | 2020-05-07 | The Wistar Institute Of Anatomy And Biology | A novel dna vaccine against crimean-congo hemorrhagic fever virus (cchfv) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8178660B2 (en) * | 2006-01-13 | 2012-05-15 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using codon optimized IL-15 and methods for using the same |
-
2022
- 2022-02-07 WO PCT/KR2022/001874 patent/WO2022169339A1/ko active Application Filing
- 2022-02-07 JP JP2023547642A patent/JP2024507733A/ja active Pending
- 2022-02-07 KR KR1020220015857A patent/KR102553857B1/ko active IP Right Grant
- 2022-02-07 EP EP22750088.1A patent/EP4306641A1/en active Pending
- 2022-02-07 CN CN202280026988.1A patent/CN117120617A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190003471A (ko) * | 2016-02-25 | 2019-01-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 지카 바이러스에 대항하는 신규한 백신 |
WO2020092880A1 (en) * | 2018-11-02 | 2020-05-07 | The Wistar Institute Of Anatomy And Biology | A novel dna vaccine against crimean-congo hemorrhagic fever virus (cchfv) |
Non-Patent Citations (3)
Title |
---|
ELSAYED, HASSAN, GHULAM NABI, WILLIAM J. MCKINSTRY, KEITH K. KHOO, JOHNSON MAK, ANDRES M. SALAZAR, MATTHIAS TENBUSCH, VLADIMIR TEM: "Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 92, no. 14, e00141-18, 1 July 2018 (2018-07-01), US , XP055956935, ISSN: 0022-538X, DOI: 10.1128/JVI.00141-18 * |
KUTZLER MICHELE A.; WEINER DAVID B.: "DNA vaccines: ready for prime time?", NATURE REVIEWS GENETICS, vol. 9, no. 10, 1 October 2008 (2008-10-01), Nature Publishing Group, GB, pages 776 - 788, XP037134884, ISSN: 1471-0056, DOI: 10.1038/nrg2432 * |
TREVOR R. F. SMITH, AMI PATEL, STEPHANIE RAMOS, DUSTIN ELWOOD, XIZHOU ZHU, JIAN YAN, EBONY N. GARY, SUSANNE N. WALKER, KATHERINE S: "Immunogenicity of a DNA vaccine candidate for COVID-19", NATURE COMMUNICATIONS, vol. 11, no. 1, 2601, 1 December 2020 (2020-12-01), XP055767550, DOI: 10.1038/s41467-020-16505-0 * |
Also Published As
Publication number | Publication date |
---|---|
CN117120617A (zh) | 2023-11-24 |
KR20220113641A (ko) | 2022-08-16 |
KR102553857B1 (ko) | 2023-07-17 |
JP2024507733A (ja) | 2024-02-21 |
EP4306641A1 (en) | 2024-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021221486A1 (en) | Vaccine composition for preventing or treating infection of sars-cov-2 | |
CN106459931B (zh) | 减毒的非洲猪瘟病毒疫苗 | |
AU2009231559B2 (en) | Consensus sequences of Chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same | |
CA2329133A1 (en) | Recombinant venezuelan equine encephalitis virus vaccine | |
WO2017095191A1 (ko) | 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물 | |
WO2019151760A1 (ko) | 신규 다가 hpv 백신 조성물 | |
WO2021172971A1 (ko) | 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물 | |
Dummer et al. | Bovine herpesvirus glycoprotein D: a review of its structural characteristics and applications in vaccinology | |
WO2022203358A1 (ko) | 약독화된 레오바이러스 기반의 백신 조성물 및 이의 용도 | |
Mingxiao et al. | Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18 | |
WO2012036391A2 (ko) | 돼지 써코바이러스2(pcv2) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주 | |
WO2022045827A1 (ko) | 신규한 코로나바이러스 재조합 스파이크 단백질, 이를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터 및 상기 벡터를 포함하는 코로나바이러스감염증 예방 또는 치료용 백신 | |
WO2019151759A1 (ko) | 신규 백신 면역보조제 | |
WO2022169339A1 (ko) | 신규 핵산 분자 | |
WO2023055078A1 (ko) | Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물 및 이의 용도 | |
Wachsman et al. | Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease | |
WO2022092769A1 (ko) | Bp26 및 항원 폴리펩타이드를 포함하는 융합 단백질 | |
WO2024035185A1 (ko) | 핵산 백신 제조용 플랫폼 | |
WO2021215857A1 (ko) | 삼량체를 형성하는 코로나-19 바이러스 (covid-19, coronavirus disease 2019)의 재조합 스파이크 단백질 및 식물에서의 상기 재조합 스파이크 단백질의 대량 생산 방법과 이를 기반으로하는 백신조성물 제조 방법 | |
Degen et al. | Host-derived cytokines and chemokines as vaccine adjuvants | |
WO2022065889A1 (ko) | 재조합 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 | |
WO2023244044A1 (ko) | 변형된 코로나바이러스 스파이크 항원 단백질 및 이의 용도 | |
WO2023048532A1 (ko) | 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도 | |
WO2020263062A1 (ko) | 구제역 바이러스 백신 조성물 | |
WO2022035248A1 (ko) | 코리스미산 이성화효소를 포함하는 결핵 예방용 백신 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22750088 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023547642 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022750088 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022750088 Country of ref document: EP Effective date: 20230905 |